Maraviroc, risks and benefits: a review of the clinical literature.

Abstract

BACKGROUND Maraviroc represents the first licensed CCR5 co-receptor antagonist from the new antiretroviral (ARV) drug-class of entry inhibitors. RESULTS Results of Phase III clinical trials in three-drug-class experienced patients have presented maraviroc as a promising new agent for treatment of HIV-1-infection. Maraviroc (b.i.d./q.d.) + optimised… (More)
DOI: 10.1517/14740338.7.5.559

Topics

Cite this paper

@article{Emmelkamp2008MaravirocRA, title={Maraviroc, risks and benefits: a review of the clinical literature.}, author={Jetske M Emmelkamp and J{\"u}rgen K. Rockstroh}, journal={Expert opinion on drug safety}, year={2008}, volume={7 5}, pages={559-69} }